Skip to main content
. 2020 Feb 26;8(1):e000146. doi: 10.1136/jitc-2019-000146

Figure 2.

Figure 2

Spider plots depicting change in tumor burden in 37 patients with PD by RECIST V.1.1 and iCR or iPR by iRECIST. (A) n=11 responders by iRECIST; black circle represents timing of progression based on increase in target lesions by RECIST V.1.1. (B) n=10 responders by iRECIST; black circle represents timing of progression based on non-target lesions by RECIST V.1.1. (C) n=16 responders by iRECIST; black circle represents timing of progression based on new lesions by RECIST V.1.1. iCR, complete response; iPR, partial response; RECIST, Response Evaluation Criteria in Solid Tumours.